Clinical trial
Phase II Study of Rituximab and Gemcitabine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Hoosier Oncology Group LYM03-64
NCT00216164 is registered in ClinicalTrials.gov with Hoosier Cancer Research Network as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Rituximab and Gemcitabine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Hoosier Oncology Group LYM03-64
- Lead sponsor
- Hoosier Cancer Research Network
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- April 30, 2005
- Completion date
- March 31, 2007
- Enrollment
- 8 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.